| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $2.35B | Trading Days | 51 |
| 52W High | 52.15 |
| 52W Low | 23.00 |
| % Off High | −14.18% |
| Ann. Volatility (1Y) | 112.31% | Ann. Volatility (3Y) | 112.31% |
| Sharpe (1Y) | 1.81 | Sharpe (3Y) | 1.81 |
| Max Drawdown (1Y) | −26.53% | Max Drawdown (3Y) | −26.53% |
| YTD | 31.62% | Since inception | 31.62% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VCEL | Vericel Corp | $2.39B | 146.0 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $2.10B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.04B | 14.6 |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.86B | — |
| IMCR | Immunocore Holdings plc | $1.70B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.57B |
| MAZE | Maze Therapeutics, Inc. | $1.54B | — |
